Testing a new antibody treatment for mild to moderate lupus

Plain-English translation of NCT06881290 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated June 2026 · How we translate trials

Read our Lupus Erythematosus, Systemic research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is a small pilot study testing vunakizumab, a new injectable medication designed to reduce inflammation in people with mild to moderate systemic lupus erythematosus (lupus). The medication works by blocking a protein called IL-17A that plays a role in lupus inflammation. This is one of the first studies to directly test this approach in lupus patients.

Lupus is a chronic disease where the immune system attacks the body's own tissues, causing pain, rashes, and organ damage. While existing treatments help some patients, doctors need more options—especially treatments that allow patients to use lower doses of steroids, which can have side effects over time. This medication has shown promise in other inflammatory diseases, and researchers believe it may work for lupus too.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have been diagnosed with lupus according to current medical guidelines
you have mild to moderate lupus activity (including skin rashes, mouth sores, or joint pain)
you have been on a stable lupus treatment regimen for at least 4 weeks, with corticosteroid dose at 20 mg or less per day
you have a body mass index between 18 and 35
you are willing and able to give informed consent and complete the study

You likely don't qualify if…

you have severe lupus affecting your brain, kidneys, heart, or lungs
you have active infections including tuberculosis or HIV
you have had cancer within the past 5 years
you have liver problems or are pregnant or breastfeeding
you have taken other biologic medications (like belimumab or rituximab) within the past 3 months

What participation looks like

As a participant, you would receive vunakizumab injections combined with your current lupus medications. The study involves regular visits to the clinic where your lupus activity, symptoms, and any side effects will be monitored through blood tests and physical exams. You will need to follow your doctor's instructions carefully and report any changes in how you feel throughout the study period.

Testing a new antibody treatment for mild to moderate lupus

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)